ストックスクリーナーアプリを入手
56.50
1.05%
-0.60
前日終値:
$57.10
開ける：
$57.19
24時間の取引高:
3.22M
Relative Volume:
1.19
時価総額：
$14.20B
収益：
$2.38B
当期純損益:
$833.42M
株価収益率:
18.73
EPS:
3.0172
ネットキャッシュフロー:
$917.69M
1週間 パフォーマンス:
+1.16%
1か月 パフォーマンス:
+7.46%
6か月 パフォーマンス:
+28.29%
1年 パフォーマンス:
+25.08%
1日の値動き範囲:
$55.66
$57.27
1週間の範囲:
$54.85
$57.57
52週間の値動き範囲:
$33.76
$57.57
Exelixis Inc Stock (EXEL) Company Profile
Compare EXEL vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
56.50 | 14.20B | 2.38B | 833.42M | 917.69M | 3.0172 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-11-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | 再開されました | Barclays | Equal Weight |
| 2025-09-17 | 再開されました | Barclays | Equal Weight |
| 2025-09-17 | 開始されました | Goldman | Buy |
| 2025-07-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2024-09-19 | 開始されました | UBS | Neutral |
| 2024-04-11 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 開始されました | BTIG Research | Buy |
| 2023-12-15 | 開始されました | Citigroup | Buy |
| 2023-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-22 | 繰り返されました | Oppenheimer | Outperform |
| 2023-08-08 | 開始されました | SVB Securities | Market Perform |
| 2023-07-11 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 再開されました | Piper Sandler | Overweight |
| 2023-03-09 | 開始されました | Wells Fargo | Overweight |
| 2023-01-26 | 開始されました | Credit Suisse | Outperform |
| 2022-10-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-11-03 | 再開されました | Jefferies | Buy |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-18 | 再開されました | Goldman | Sell |
| 2021-03-31 | 開始されました | Credit Suisse | Outperform |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-03-18 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 開始されました | Goldman | Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Underweight |
| 2018-05-11 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-10-16 | 繰り返されました | SunTrust | Buy |
| 2017-09-22 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-09-12 | 繰り返されました | Needham | Buy |
| 2017-07-14 | 開始されました | SunTrust | Buy |
| 2017-03-31 | 開始されました | Needham | Buy |
| 2017-03-16 | 開始されました | Oppenheimer | Perform |
| 2017-02-28 | ダウングレード | Stifel | Buy → Hold |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2016-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 繰り返されました | Stifel | Buy |
すべてを表示
Exelixis Inc (EXEL) 最新ニュース
Exelixis (EXEL) Stock Trades At A Discount After Its 236% Run - Yahoo Finance
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth? - Yahoo Finance
Exelixis Announces Zanzalintinib in Combinati - Moomoo
Exelixis: STELLAR-303 Results Mixed, STELLAR-304 Success Likely (NASDAQ:EXEL) - Seeking Alpha
Exelixis, Inc. (EXEL) hit a 52-week high, can the run continue? - MSN
Is Exelixis, Inc. (EXEL) Among the Best Under-the-Radar Stocks to Invest In? - Yahoo Finance
Handa, Intas Face Patent Suits Over Exelixis Cancer Drug - Law360
Exelixis focuses on oncology pipeline as Nasdaq-listed biotech pursues growth - ad-hoc-news.de
Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Exelixis (EXEL) Goldman Sachs 47th Annual Global Healthcare Conference 2026 Summary - Quartr
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June - AOL.com
Axsome Therapeutics, Exelixis, Incyte Among 20 New Stocks On IBD's Premier Watchlists - Investor's Business Daily
EXEL Maintained by RBC Capital -- Price Target Raised to $46.00 - GuruFocus
Exelixis Inc stock hits all-time high at 56.22 USD - Investing.com
Exelixis Inc stock hits all-time high at 56.22 USD By Investing.com - Investing.com Nigeria
Truist Financial Maintains Exelixis(EXEL.US) With Hold Rating, Raises Target Price to $56 - Moomoo
RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating - marketscreener.com
(EXEL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with Strong Revenue Growth and High Analyst Interest - DirectorsTalk Interviews
Zanzalintinib Trial Outcomes And Index Exit Might Change The Case For Investing In Exelixis (EXEL) - simplywall.st
ETFs Investing in Exelixis, Inc. Stocks - TradingView
Price to sales forward of Exelixis, Inc. – NASDAQ:EXEL - TradingView
Exelixis, Inc. (EXEL) Stock Price Today - CoinMarketCap
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Santhera Pharmaceuticals Holding (OtherSPHDF) - The Globe and Mail
Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says - marketscreener.com
UBS raises Exelixis stock price target to $52 on pipeline outlook - Investing.com Nigeria
UBS Adjusts Price Target on Exelixis to $52 From $43, Maintains Neutral Rating - marketscreener.com
EXEL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $56 - GuruFocus
H.C. Wainwright reiterates Exelixis stock rating at Buy, $56 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Exelixis stock rating at Buy, $56 target - Investing.com
Analyst recommendations: Adobe, AA, Nike, Exelixis… - marketscreener.com
What Does Truist’s New Analyst Think About Exelixis (EXEL) and Its Next-Generation Cancer Drug? - Yahoo Finance
Exelixis | 4: Statement of changes in beneficial ownership of securities-Officer Aftab Dana - Moomoo
Exelixis Inc. (NASDAQ:EXEL): A Decent Value Play in the Biotechnology Sector - ChartMill
Seven Fleet Capital Management LP's Exelixis Inc(EXEL) Holding History - GuruFocus
Exelixis, Inc.(NasdaqGS: EXEL) dropped from Russell 1000 Value-Defensive Index - marketscreener.com
Exelixis, Inc.(NasdaqGS: EXEL) dropped from Russell 1000 Growth-Defensive Index - marketscreener.com
Exelixis, Inc.(NasdaqGS: EXEL) dropped from Russell 1000 Defensive Index - marketscreener.com
Exelixis, Inc. (EXEL) Stock Analysis: Biotechnology Leader with Robust Revenue Growth and High ROE - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Enterprise value to EBITDA forward of Exelixis, Inc. – NASDAQ:EXEL - TradingView
Price to sales forward of Exelixis, Inc. – GETTEX:EX9 - TradingView
Enterprise value to EBITDA forward of Exelixis, Inc. – GETTEX:EX9 - TradingView
Exelixis falls as final analysis of zanzalintinib Phase 3 data disappoints - MSN
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib - MSN
Exelixis stock reaches all-time high of 53.97 USD By Investing.com - Investing.com South Africa
Exelixis stock reaches all-time high of 53.97 USD - Investing.com
Exelixis, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh Actuals & Estimates (BMFBOVESPA:E2XE34) - TradingView
Enterprise value to revenue forward of Exelixis, Inc. – NASDAQ:EXEL - TradingView
Exelixis Inc (EXEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Liquidity Mapping Around (EXEL) Price Events - Stock Traders Daily
Exelixis Inc (EXEL) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):